Information Provided By:
Fly News Breaks for May 17, 2017
BSX
May 17, 2017 | 07:56 EDT
RBC Capital analyst Glenn Novarro says clinical data gives him confidence that Boston Scientific's Lotus platform "can become a viable competitor" in the U.S. The analyst keeps a $29 price target and an Outperform rating on the shares.
News For BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.